Christina Tartaglia is a Managing Director at Stern IR. Since joining Stern IR in 2015, Christina has worked with a broad spectrum of private and public biotechnology companies in the US, Europe and Asia, in all stages of development from preclinical to commercial commercials. Christina has worked with platform companies focused on drug discovery using advanced computational technologies, novel therapeutic modalities including gene and cell therapy as well as clinical and commercial companies in various therapeutic areas including oncology, rare disease, immunology, hepatology, allergy, and central nervous system diseases.
Christina has advised companies through many types of financings, developing strategic plans for early and later stage private and crossover rounds, as well as accessing the public markets through initial public offerings, reserve mergers, follow-ons and mergers and acquisitions. Christina is experienced in implementing effective messaging strategies for complex science stories and clinical trial data announcements, as well as for situations including management transitions, commercial launch preparations, corporate restructuring, rebrands, and business development announcements. Christina enjoys working closely with management teams and watching companies grow and succeed in achieving their goals.
Before joining Stern IR, Christina worked in both clinical and bench research relating to various stages of drug discovery and development. She is also a co-founder and board member of The Scientista Foundation, an organization devoted to empowering pre-professional women in STEM fields.
Christina holds an A.B. in Molecular and Cellular Biology and a secondary field in Health Policy from Harvard College as well as a Business Certificate from Columbia University.